SBFM - Sunshine Biopharma Moves Principal Office to New York City
NEW YORK, Dec. 04, 2023 (GLOBE NEWSWIRE) -- Sunshine Biopharma, Inc. (NASDAQ: “SBFM”) (the “Company”), a pharmaceutical company offering and researching life-saving medicines in a variety of therapeutic areas including oncology and antivirals today announced that it has moved its headquarters to New York City. The Company’s Head Office is now located at 1177 Avenue of the Americas, 5 th Floor, New York, NY 10036 (Tel: 332-216-1147). The Company will maintain a satellite office at its previous headquarters in Montreal (Canada) at 6500 Trans-Canada Highway, 4 th Floor, Pointe-Claire, Quebec, Canada, H9R 0A5 (Tel: 514-426-6161). The Company’s email address ( info@sunshinebiopharma.com ) and URL ( www.sunshinebiopharma.com ) have not changed.
Ab o ut S u n s hi n e B i o p h a r m a
Sunshine Biopharma is a pharmaceutical company operating a Canadian wholly owned subsidiary (Nora Pharma Inc.) with 41 employees and 51 generic prescription drugs on the market in Canada. The Company is planning to expand its product offering to a total of 67 generic prescription drugs by the end of 2024. In addition, Sunshine Biopharma is conducting a proprietary drug development program which is comprised of (i) K1.1 mRNA for liver cancer, and (ii) PLpro protease inhibitor for COVID-19. For more information, please visit: www.sunshinebiopharma.com.
S af e Ha rb o r F o rw a r d - L oo k i ng St a t e m en t s
T h is p r e s s r ele a s e c on t a i n s f o r w a r d- l oo ki n g s t a tem en ts wh ich a r e ba s ed o n c u rr e n t e xp e c t a ti on s , f o r e ca s t s , a n d a ss u m p ti on s o f Sun s h i n e Bi o p ha r m a , In c. ( t h e “ C o m pan y”) t ha t i n v o lve r i s ks a s w e l l a s un c e r t a i n ties t ha t c ou ld c au s e a ct ua l o u tc o mes an d r es u lts to d iffer m a ter i a lly f r o m t ho s e an tici pa ted o r e xp e c te d . T h e s e s t a tem en ts app e a r in t h is r ele a s e an d i n cl ud e a ll s t a tem en ts t ha t a r e no t s t a tem en ts o f h i s t o r ic a l f a ct r e ga r d i n g t h e i n te n t, b elief o r c u rr e n t e xp e c t a ti on s o f t h e C o m p an y, i n cl ud i n g s t a tem en ts r el a ted to t h e C o m p an y ’ s d r u g d e v el o p me n t a ctivities, fi nan c i a l p erfo r m an c e , a n d f u t u r e g row t h . T h ese r i s ks an d un c e r t a i n ties a r e f u r t h er d esc r i b ed in fil i ng s an d r e po r ts b y t h e C o m pan y w ith t h e U .S . S e cu r i ties an d Ex cha n g e C o mmis s i o n (S E C ) . Act ua l r es u lts an d t h e timi n g o f c e r t a in e v e n ts c ou ld d iffer m a ter i a lly f r o m t h o s e p r o ject e d in o r c on tem p l a t ed b y t h e f o rw a r d - l oo ki n g s t a tem en ts du e to a nu m b er o f f a ct o r s d et a iled f r o m time to time in t h e C o m pan y ’ s fil i ng s w ith t h e S E C . Refere n ce is h ere b y m ad e to c au ti o n a r y s t a tem en ts an d r i s k f a ct o r s s et f o r th in t h e C o m pan y ’ s m o s t rec en t S EC fil i ng s .
F o r Add i t i o n a l I n fo r m at i o n:
Sunshine Biopharma Contact:
Camille Sebaaly, CFO
Direct Line: 514-814-0464
camille.sebaaly@sunshinebiopharma.com